Loading…
Lobbying Spend
—
Filings
214
Firms Hired
5
Active Period
2006–2026
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
H.R.5269/2761 - RESULTS Act Issues related to Medicare coverage and reimbursement for FDA-designated breakthrough medical devices, focusing on establishing a transitional coverage period, including H.R. 5343/S. 1717- Ensuring Patient Access to Critical Breakthrough Products Act of 2025.
Client expense: — · Firm income: $40,000
Matched citations: H.R.5269
Ensuring Patient Access to Critical Breakthrough Products Act
2026 · third_quarter · Firm: THE MCMANUS GROUP
H.R.5269/2761 - RESULTS Act Issues related to Medicare coverage and reimbursement for FDA-designated breakthrough medical devices, focusing on establishing a transitional coverage period, including H.R. 5343/S. 1717- Ensuring Patient Access to Critical Breakthrough Products Act of 2025.
Client expense: — · Firm income: $40,000
Matched citations: H.R. 5343
Ensuring Patient Access to Critical Breakthrough Products Act of 2025
2026 · third_quarter · Firm: THE MCMANUS GROUP
H.R.5269/2761 - RESULTS Act Issues related to Medicare coverage and reimbursement for FDA-designated breakthrough medical devices, focusing on establishing a transitional coverage period, including H.R. 5343/S. 1717- Ensuring Patient Access to Critical Breakthrough Products Act of 2025.
Client expense: — · Firm income: $40,000
Matched citations: S. 1717
Ensuring Patient Access to Critical Breakthrough Products Act; HR 5269: Reforming and Enhancing Sustainable Updates to Laboratory Testing Services Act
Client expense: — · Firm income: $30,000
Matched citations: HR 5269
Ensuring Patient Access to Critical Breakthrough Products Act; HR 5269: Reforming and Enhancing Sustainable Updates to Laboratory Testing Services Act
Client expense: — · Firm income: $30,000
Matched citations: HR 5269
H.R.5269/2761 - RESULTS Act Issues related to Medicare coverage and reimbursement for FDA-designated breakthrough medical devices, focusing on establishing a transitional coverage period, including H.R. 5343/S. 1717- Ensuring Patient Access to Critical Breakthrough Products Act of 2025.
Client expense: — · Firm income: $40,000
Matched citations: H.R.5269
Ensuring Patient Access to Critical Breakthrough Products Act
2026 · second_quarter · Firm: THE MCMANUS GROUP
H.R.5269/2761 - RESULTS Act Issues related to Medicare coverage and reimbursement for FDA-designated breakthrough medical devices, focusing on establishing a transitional coverage period, including H.R. 5343/S. 1717- Ensuring Patient Access to Critical Breakthrough Products Act of 2025.
Client expense: — · Firm income: $40,000
Matched citations: H.R. 5343
Ensuring Patient Access to Critical Breakthrough Products Act of 2025
2026 · second_quarter · Firm: THE MCMANUS GROUP
H.R.5269/2761 - RESULTS Act Issues related to Medicare coverage and reimbursement for FDA-designated breakthrough medical devices, focusing on establishing a transitional coverage period, including H.R. 5343/S. 1717- Ensuring Patient Access to Critical Breakthrough Products Act of 2025.
Client expense: — · Firm income: $40,000
Matched citations: S. 1717
Ensuring Patient Access to Critical Breakthrough Products Act; HR 5269: Reforming and Enhancing Sustainable Updates to Laboratory Testing Services Act
Client expense: — · Firm income: $30,000
Matched citations: HR 5269
H.R.5269/2761 - RESULTS Act Issues related to Medicare coverage and reimbursement for FDA-designated breakthrough medical devices, focusing on establishing a transitional coverage period, including H.R. 5343/S. 1717- Ensuring Patient Access to Critical Breakthrough Products Act of 2025.
Client expense: — · Firm income: $40,000
Matched citations: H.R.5269
Ensuring Patient Access to Critical Breakthrough Products Act
2026 · first_quarter · Firm: THE MCMANUS GROUP
H.R.5269/2761 - RESULTS Act Issues related to Medicare coverage and reimbursement for FDA-designated breakthrough medical devices, focusing on establishing a transitional coverage period, including H.R. 5343/S. 1717- Ensuring Patient Access to Critical Breakthrough Products Act of 2025.
Client expense: — · Firm income: $40,000
Matched citations: H.R. 5343
Ensuring Patient Access to Critical Breakthrough Products Act of 2025
2026 · first_quarter · Firm: THE MCMANUS GROUP
H.R.5269/2761 - RESULTS Act Issues related to Medicare coverage and reimbursement for FDA-designated breakthrough medical devices, focusing on establishing a transitional coverage period, including H.R. 5343/S. 1717- Ensuring Patient Access to Critical Breakthrough Products Act of 2025.
Client expense: — · Firm income: $40,000
Matched citations: S. 1717
Ensuring Patient Access to Critical Breakthrough Products Act; HR 5269: Reforming and Enhancing Sustainable Updates to Laboratory Testing Services Act
Client expense: — · Firm income: $30,000
Matched citations: HR 5269
H.R.5269/2761 - RESULTS Act Issues related to Medicare coverage and reimbursement for FDA-designated breakthrough medical devices, focusing on establishing a transitional coverage period, including H.R. 5343/S. 1717- Ensuring Patient Access to Critical Breakthrough Products Act of 2025.
Client expense: — · Firm income: $40,000
Matched citations: H.R.5269
Ensuring Patient Access to Critical Breakthrough Products Act
2025 · fourth_quarter · Firm: THE MCMANUS GROUP
H.R.5269/2761 - RESULTS Act Issues related to Medicare coverage and reimbursement for FDA-designated breakthrough medical devices, focusing on establishing a transitional coverage period, including H.R. 5343/S. 1717- Ensuring Patient Access to Critical Breakthrough Products Act of 2025.
Client expense: — · Firm income: $40,000
Matched citations: H.R. 5343
Ensuring Patient Access to Critical Breakthrough Products Act of 2025
2025 · fourth_quarter · Firm: THE MCMANUS GROUP
H.R.5269/2761 - RESULTS Act Issues related to Medicare coverage and reimbursement for FDA-designated breakthrough medical devices, focusing on establishing a transitional coverage period, including H.R. 5343/S. 1717- Ensuring Patient Access to Critical Breakthrough Products Act of 2025.
Client expense: — · Firm income: $40,000
Matched citations: S. 1717
Ensuring Patient Access to Critical Breakthrough Products Act; HR 5269: Reforming and Enhancing Sustainable Updates to Laboratory Testing Services Act
Client expense: — · Firm income: $30,000
Matched citations: HR 5269
Ensuring Patient Access to Critical Breakthrough Products Act
2025 · third_quarter · Firm: THE MCMANUS GROUP
Access to and reimbursement of medical devices, specifically diagnostics, in the Medicare program. Issues related to Medicare reimbursement for clinical laboratory services under the Clinical Laboratory Fee Schedule (CLFS), specifically reforms to address payment cuts resulting from the Protecting Access to Medicare Act (PAMA) of 2014. Issues related to Medicare coverage and reimbursement for FDA-designated breakthrough medical devices, focusing on establishing a transitional coverage period, including H.R. 5343/S. 1717- Ensuring Patient Access to Critical Breakthrough Products Act of 2025.
Client expense: — · Firm income: $40,000
Matched citations: H.R. 5343
Ensuring Patient Access to Critical Breakthrough Products Act of 2025
2025 · third_quarter · Firm: THE MCMANUS GROUP
Access to and reimbursement of medical devices, specifically diagnostics, in the Medicare program. Issues related to Medicare reimbursement for clinical laboratory services under the Clinical Laboratory Fee Schedule (CLFS), specifically reforms to address payment cuts resulting from the Protecting Access to Medicare Act (PAMA) of 2014. Issues related to Medicare coverage and reimbursement for FDA-designated breakthrough medical devices, focusing on establishing a transitional coverage period, including H.R. 5343/S. 1717- Ensuring Patient Access to Critical Breakthrough Products Act of 2025.
Client expense: — · Firm income: $40,000
Matched citations: S. 1717
Ensuring Patient Access to Critical Breakthrough Products Act of 2025
2025 · second_quarter · Firm: THE MCMANUS GROUP
Access to and reimbursement of medical devices, specifically diagnostics, in the Medicare program. Issues related to Medicare reimbursement for clinical laboratory services under the Clinical Laboratory Fee Schedule (CLFS), specifically reforms to address payment cuts resulting from the Protecting Access to Medicare Act (PAMA) of 2014. Issues related to Medicare coverage and reimbursement for FDA-designated breakthrough medical devices, focusing on establishing a transitional coverage period, including S. 1717- Ensuring Patient Access to Critical Breakthrough Products Act of 2025
Client expense: — · Firm income: $40,000
Matched citations: S. 1717
Saving Access to Laboratory Services Act
2025 · first_quarter · Firm: DS2 GROUP, LLC
HR 8188 Saving Access to Laboratory Services Act
Client expense: — · Firm income: $30,000
Matched citations: HR 8188
Ensuring Patient Access to Critical Breakthrough Products Act of 2024
2024 · fourth_quarter · Firm: THE MCMANUS GROUP
H.R.1691 - Ensuring Patient Access to Critical Breakthrough Products Act of 2023 S.5349 - Ensuring Patient Access to Critical Breakthrough Products Act of 2024
Client expense: — · Firm income: $40,000
Matched citations: H.R.1691
Ensuring Patient Access to Critical Breakthrough Products Act of 2024
2024 · fourth_quarter · Firm: THE MCMANUS GROUP
H.R.1691 - Ensuring Patient Access to Critical Breakthrough Products Act of 2023 S.5349 - Ensuring Patient Access to Critical Breakthrough Products Act of 2024
Client expense: — · Firm income: $40,000
Matched citations: S.5349
Saving Access to Laboratory Services Act
2024 · fourth_quarter · Firm: DS2 GROUP, LLC
HR 8188 Saving Access to Laboratory Services Act
Client expense: — · Firm income: $30,000
Matched citations: HR 8188
Ensuring Patient Access to Critical Breakthrough Products Act of 2024
2024 · third_quarter · Firm: THE MCMANUS GROUP
H.R.1691 - Ensuring Patient Access to Critical Breakthrough Products Act of 2023
Client expense: — · Firm income: $10,000
Matched citations: H.R.1691
Source: Senate LDA